Basal-like breast cancers (BLBCs) express genes characteristic of myoepithelial/basal cells in the normal mammary gland and comprise up to 25% of all breast cancers. Chemotherapy is the only systemic therapy for BLBC, which underexpresses estrogen receptor (ER), progesterone receptor, and HER-2. It preferentially affects younger women and African-American women, and is associated with high histological grade, aggressive clinical behavior, and a high rate of metastasis to the lung and brain. Unlike other breast cancer subtypes, there is no correlation between tumor size and lymph node metastasis. To date, little is known about the molecular basis of BLBC. We have found that the transcription factor FOXC1, which is involved in embryonic development, is consistently and exclusively induced in BLBC and is associated with poor overall survival. FOXC1 overexpression in normal breast epithelial cells and breast cancer cells increased cell proliferation, migration, invasion, and protein levels of NF-kB p65 and ?-catenin. We therefore hypothesize that FOXC1 is a critical marker and functional regulator of BLBC via modulating NF-kB activation and ?-catenin signaling. In addition, we hypothesize that expression of FOXC1, repressed by ER but elicited by ERK/Notch signaling, determines the propensity of BLBC to metastasize to the brain and lung.
In Aim 1, we will determine whether FOXC1 regulates cell growth, migration, invasion, and stem cell-like properties of BLBC cells by activating NF-kB and ?-catenin signaling. FOXC1 overexpression and knockdown cell models will be used to examine the mechanisms and effects of the upregulation of p65 and ?-catenin by FOXC1.
In Aim 2, we will determine whether FOXC1 regulates BLBC development in vivo and predisposes breast cancer to brain and lung metastasis. The MMTV-FOXC1 transgenic mouse model will be used to investigate the role of FOXC1 in BLBC development. A brain-seeking xenograft model and the metastatic 4T1 syngeneic mouse mode will be used to study whether FOXC1 governs preferential BLBC metastasis to the brain and lung, respectively.
In Aim 3, we will define the molecular mechanisms responsible for upstream regulation of FOXC1 overexpression in BLBC. We will investigate whether EGF induces FOXC1 expression in BLBC cells through downstream ERK and Notch signaling, and whether Notch and ER mediate BRCA1 inhibition of FOXC1 transcription. BLBC is a poorly understood area that is of paramount importance in breast cancer. By providing insight into the biological mechanism for BLBC, this study will facilitate establishing a critical functional marker for detection and diagnosis of BLBC. Results may warrant development and clinical investigation of agents that block FOXC1. Finally, understanding how FOXC1 expression is regulated may allow development of FOXC1-based strategies to prevent BLBC.

Public Health Relevance

Basal-like breast cancer is a subtype of breast cancer which has the worst prognosis and is poorly understood. Chemotherapy is the only systemic treatment for these breast cancers. Our study will help establish a critical molecular marker for detection and diagnosis of basal-like cancers, and also help uncover the biological basis for the cellular traits and phenotypes of basal-like breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA151610-03
Application #
8450164
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2011-02-14
Project End
2016-01-31
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
3
Fiscal Year
2013
Total Cost
$325,734
Indirect Cost
$130,684
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Shen, Songjie; Sun, Qiang; Liang, Zhiyong et al. (2014) A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status. PLoS One 9:e100664
Qu, Ying; Zhou, Chenfei; Zhang, Jianian et al. (2014) The metastasis suppressor SOX11 is an independent prognostic factor for improved survival in gastric cancer. Int J Oncol 44:1512-20
Jin, Yanli; Han, Bingchen; Chen, Jiongyu et al. (2014) FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer. Ann Surg Oncol 21 Suppl 4:S758-66
Cheon, Dong-Joo; Tong, Yunguang; Sim, Myung-Shin et al. (2014) A collagen-remodeling gene signature regulated by TGF-* signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res 20:711-23
Chung, Alice; Cui, Xiaojiang; Audeh, William et al. (2013) Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer 13:223-32
Qu, Ying; Ray, Partha S; Li, Jianfang et al. (2013) High levels of secreted frizzled-related protein 1 correlate with poor prognosis and promote tumourigenesis in gastric cancer. Eur J Cancer 49:3718-28
Wang, Liyang; Hou, Yixuan; Sun, Yan et al. (2013) c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion. Mol Oncol 7:1116-28
Bagaria, Sanjay P; Ray, Partha S; Wang, Jinhua et al. (2012) Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol 19:935-40